ITeos Therapeutics (ITOS) Stock Highlights

7.85 | -0.63%

2024-11-21 04:59:35

ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.

Statistics

Range Today

7.82 8.38

Volume Today 502.3K

Range 1 Year

7.66 18.75

Volume 1 Year 109.19M

Range 3 Year

7.66 52.43

Volume 3 Year 306.01M

Range 10 Year

7.66 52.43

Volume 10 Year 394.61M

Highlights

Market Capitalization 338.56M (small)

Floating Shares 23.93M

Current Price 7.85

Price To Earnings -3.04

Price To Revenue -6.49

Price To Book 0.51

Earnings Per Share -2.99

Payout Ratio 0%

Performance

Latest -0.63%

1 Month -16.04%

3 Months -52.34%

6 Months -56.49%

1 Year -22.66%

3 Years -79.36%

5 Years -69.28%

10 Years -69.28%

Benchmarks

Market Capitalization

182 / 368

Gross Profits

26 / 278

Total Revenue

108 / 300

Total Rank

167 / 368

Free Cashflow

286 / 352

Performance 5 years

205 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.